Long-term effects of empagliflozin in patients with chronic kidney disease

<p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to asses...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R
Další autoři:	EMPA-KIDNEY Collaborative Group
Médium:	Journal article
Jazyk:	English
Vydáno:	Massachusetts Medical Society 2024

Long-term effects of empagliflozin in patients with chronic kidney disease

Podobné jednotky